Skip to main content
. 2018 Sep 29;10(10):365. doi: 10.3390/cancers10100365

Table 2.

Drugs/inhibitors used in this study and their molecular targets.

Drug/Inhibitor Molecular Target
Temsirolimus mTOR, FKBP12
Everolimus mTOR, FKBP12
Sunitinib VEGFR2 (Flk-1) and PDGFRβ
Sorafenib Raf-1, B-Raf and VEGFR-2
Pazopanib VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms
Afuresertib (GSK2110183) Akt
Sapitinib (AZD8931) EGFR, ErbB2 and ErbB3
FLI-06 Notch
U73122 Phospholipase C (PLC)